Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
06/2002
06/25/2002US6410263 Histidine kinase
06/25/2002US6410255 Optical probes and assays
06/25/2002US6410249 Odorant receptors
06/25/2002US6410063 Composition and method
06/25/2002US6410054 Immediate release eplerenone compositions
06/25/2002US6410021 Vaccines of pasteurellaceae mutants and vaccination method
06/25/2002US6410019 Topical administration of immunoglobulins brings about remission of inflammatory process without causing any toxic or unwanted side effects
06/25/2002US6410011 Treatment of restenosis by gene therapy, comprising the administration of a recombinant adenovirus containing a suicide gene
06/25/2002US6410010 Recombinant P53 adenovirus compositions
06/25/2002US6410007 Erectile dysfunction, vasodilation
06/25/2002CA2245462C Methods of modulating cell proliferation through telomerase modulation
06/25/2002CA2240964C Piperidone tachykinin antagonists
06/25/2002CA2220024C Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents
06/25/2002CA2213609C New compounds to modulate hormone receptors, compositions containing them, and their therapeutic use
06/25/2002CA2208351C Chalcones and esters thereof with antiproliferative activity in uterus, ovary and breast tumours
06/25/2002CA2203878C Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands
06/25/2002CA2140281C Analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis
06/25/2002CA2136893C Substituted n-piperidino-pyrazole-3-carboxamide
06/25/2002CA2135648C Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
06/25/2002CA2017379C Purification and characterization of a glioma-derived growth factor
06/22/2002CA2365673A1 Methods, compositions and kits relating to cardiovascular disease
06/21/2002CA2365818A1 Personal care compositions
06/20/2002WO2002048368A2 Proteins associated with cell growth, differentiation, and death
06/20/2002WO2002048366A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
06/20/2002WO2002048365A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
06/20/2002WO2002048363A2 Human transporter proteins, nucleic acid molecules encoding them, and uses thereof
06/20/2002WO2002048351A2 A method for in vitro molecular evolution of protein function
06/20/2002WO2002048349A1 Polypeptide capable of binding to heparin
06/20/2002WO2002048337A2 Secreted human proteins
06/20/2002WO2002048182A2 Interferon-alpha induced gene
06/20/2002WO2002048172A2 Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
06/20/2002WO2002048169A1 14(15)-unsaturated 15- and/or 16- substituted androgens with mixed androgen-progestational profile
06/20/2002WO2002048166A1 Indolocarbazole anticancer agents and methods of using them
06/20/2002WO2002048165A2 Antiviral agents for treatment of flaviviridae infections
06/20/2002WO2002048152A2 Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
06/20/2002WO2002048145A1 Aminotriazolopyridiine derivatives as adenosine receptor ligands
06/20/2002WO2002048144A1 Pyrrolo (2.1-a) dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors
06/20/2002WO2002048138A1 Antimicrobial quinolones
06/20/2002WO2002048135A1 Tak1 inhibitors
06/20/2002WO2002048134A2 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists
06/20/2002WO2002048124A2 Piperazine derivatives
06/20/2002WO2002048117A1 Quinazolinone derivatives
06/20/2002WO2002048114A1 Phenylacetamido- pyrazole derivatives and their use as antitumor agents
06/20/2002WO2002048112A2 7-heterocyclyl quinoline and thieno[2,3-b]pyridine derivatives useful as antagonists of gonadotropin releasing hormone
06/20/2002WO2002048110A2 Composition for regulating animal growth, method of manufacture and use thereof
06/20/2002WO2002048106A2 Isoindolin-1-one glucokinase activators
06/20/2002WO2002048096A1 Hydrazone derivatives and use thereof in medicines
06/20/2002WO2002047762A1 Serine protease inhibitors
06/20/2002WO2002047728A2 Treatment of posterior capsule opacification
06/20/2002WO2002047723A1 Medicinal compositions having improved water-solubility
06/20/2002WO2002047721A1 Silensed anti-cd28 antibodies and use thereof
06/20/2002WO2002047711A2 Modulators of activity of g-protein-coupled receptor kinases
06/20/2002WO2002047708A2 Selective cox-2 inhibition from edible plant extracts
06/20/2002WO2002047707A2 Selective cox-2 inhibition from non-edible plant extracts
06/20/2002WO2002047706A2 Selective cox-2 inhibition from plant extracts
06/20/2002WO2002047702A1 Compositions for inducing secretion of insulin-like growth factor-1
06/20/2002WO2002047701A1 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity
06/20/2002WO2002047694A1 Pharmaceutical compositions for treatment of digestive disorders and associated diseases
06/20/2002WO2002047692A1 Use of an oestrogen in the manufacture of a composition containing oestrogen for the treatment of atrophic vaginitis
06/20/2002WO2002047687A1 Urotensin-ii receptor antagonists
06/20/2002WO2002047678A1 Antilipemic agents
06/20/2002WO2002047673A2 Methods and compositions to treat conditions associated with neovascularization
06/20/2002WO2002047668A2 Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
06/20/2002WO2002047667A2 Novel medicament compositions based on anticholinesterase drugs and on a steroid
06/20/2002WO2002047656A1 Compositions for retarding skin aging
06/20/2002WO2002047649A1 Composition containing 7-hydroxy dhea and/or 7-keto dhea and at least a carotenoid
06/20/2002WO2002047615A2 Oral compositions and use thereof
06/20/2002WO2002047493A2 Health promoting compositions
06/20/2002WO2002047474A1 Transgenic animal expressing hla-a24 and utilization thereof
06/20/2002WO2002040019A8 Benzimidazole derivatives
06/20/2002WO2002032375A3 Uses of monoclonal antibody 8h9
06/20/2002WO2002030888A3 Tricyclic compounds and uses thereof
06/20/2002WO2002028905A3 Human anti-cd40 antibodies
06/20/2002WO2002028406A3 Induction of blood vessel formation by polynucleotides encoding sphingosine kinases
06/20/2002WO2002024681A3 Pyrazine derivatives as modulators of tyrosine kinases
06/20/2002WO2002020495A3 Inhibitors of glycogen synthase kinase 3
06/20/2002WO2002020013A3 A method for treating allergies using substituted pyrazoles
06/20/2002WO2002012243A3 SYNTHESIS OF (R)-3-(4-BROMOBENZYL)-1-(3,5-DICHLOROPHENYL)-5-IODO-3-METHYL-1-H-IMIDAZO[1,2-a]IMIDAZOL-2-ONE
06/20/2002WO2002012214A3 Non-imidazole aryloxyalkylamines as h3 receptor ligands
06/20/2002WO2002011719A3 Lipase inhibitors for the treatment of dyspepsia
06/20/2002WO2002008226A3 Tricyclic 2-pyridone compounds useful as hiv reverse transcriptase inhibitors
06/20/2002WO2002004422A3 Heterocycle carboxamides as antiviral agents
06/20/2002WO2002003910A3 Antibacterial, antioxidant, immunomoduling and anticancerogenic preparation and method for using said preparation
06/20/2002WO2002000711A3 Ev-vegf nucleic acids and polypeptides and methods of use
06/20/2002WO2001098518A3 Biotransformation of biologically active compounds made of various classes of chemical substances by means of laccase and manganese peroxidase enzymes
06/20/2002WO2001094613A3 Methods and compounds for influencing beta3 integrin-dependent intracellular processes
06/20/2002WO2001091797A3 Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds
06/20/2002WO2001089570A3 Combination of growth hormone secretagogues and antidepressants
06/20/2002WO2001085942A3 Cytoskeleton-associated proteins
06/20/2002WO2001085941A3 Myc targets
06/20/2002WO2001085096A3 Mast cell regulation
06/20/2002WO2001083524A3 Rna metabolism proteins
06/20/2002WO2001078699A3 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
06/20/2002WO2001077113A3 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
06/20/2002WO2001076576A3 A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
06/20/2002WO2001072830A3 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction
06/20/2002WO2001068851A3 Polypeptides and nucleic acids encoding same
06/20/2002WO2001068698A3 Non-selective cation channel
06/20/2002WO2001068068A3 Compounds capable of binding with the cytoskeleton
06/20/2002WO2001068066A3 A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
1 ... 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 ... 1564